Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

Bergman, Martin; Zueger, Patrick; Patel, Jayeshkumar; Saffore, Christopher D.; Topuria, Ia; Cavanaugh, Cristi; Fang, Siran; Clewell, Jerry; Ogdie, Alexis

doi:10.1007/s40744-022-00504-2

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management of AS is associated with significant economic burden by way of high direct medical costs (e.g., pharmacy, inpatient, outpatient, and emergency department [ED] visits) and increasing impairment of work and daily living abilities [ 5 ]. Indeed, retrospective claims database studies have demonstrated substantial all-cause medical costs, pharmacy costs, and overall health care resource utilization among patients with active AS [ 6 , 7 ]. Moreover, patients with greater disease severity at the time of treatment initiation and those not achieving disease control had significantly greater disease-associated costs than patients with milder disease or those who achieved disease control [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Indeed, retrospective claims database studies have demonstrated substantial all-cause medical costs, pharmacy costs, and overall health care resource utilization among patients with active AS [ 6 , 7 ]. Moreover, patients with greater disease severity at the time of treatment initiation and those not achieving disease control had significantly greater disease-associated costs than patients with milder disease or those who achieved disease control [ 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Walsh,

Saffore,

Collins

et al. 2023

Rheumatol Ther

View full text Add to dashboard Cite

Introduction Recent changes to treatment guidelines for ankylosing spondylitis (AS) have listed first-line advanced therapies as tumor necrosis factor (TNF), interleukin (IL)-17, and Janus kinase (JAK) inhibitors. This study sought to assess the comparative clinical and economic benefit of advanced therapies approved for AS. Methods A systematic literature review was conducted to identify randomized clinical trials for JAK inhibitors (upadacitinib [UPA], tofacitinib [TOF]), anti-IL-17 therapies (secukinumab [SEC], ixekizumab [IXE]), and TNF inhibitors (adalimumab [ADA], etanercept [ETN], golimumab [GOL]) used for the treatment of active AS. Clinical efficacy was evaluated by Assessment of Spondyloarthritis International Society 40 (ASAS40) criteria and treatment discontinuation due to adverse events (AEs) was used to generate response rates synthesized via a Bayesian network meta-analysis. Number needed to treat (NNT) was calculated as the reciprocal of incremental response rate of each treatment versus placebo. Cost per ASAS40 responder (CPR) was calculated as the 16-week treatment costs divided by ASAS40 response rates. Data were stratified by biologic treatment status (i.e., biologic naïve [bio-naïve] or inadequate response or intolerance to biologics [bio-IR]) for efficacy and CPR analyses. Results Among bio-naïve patients, the response rate for ASAS40 was 53.6% for UPA-treated patients, whereas most other treatments had response rates between 41% and 49%. NNTs were lowest for UPA-treated patients at 2.8 (other therapies 3.2–4.8). Estimated CPR among UPA-treated patients was lowest (UPA $39.5k vs others $44.2k–102.5k). Efficacy and CPR trends were similar among bio-IR and TNF-IR patients. Among bio-naïve and bio-IR patients, the rate of AEs leading to discontinuation was lowest among UPA and SEC-treated patients (0.0, others 0.6–3.7%). Conclusions Relative to other treatments assessed in this study, UPA demonstrated numerically greater clinical and economic benefit for the treatment of AS. Head-to-head or real-world comparisons of these therapies are warranted and may inform clinical decision-making. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-023-00586-6.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Walsh,

Saffore,

Collins

et al. 2023

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

Patient-Reported and Economic Racial and Ethnic Disparities in Patients with Psoriatic Arthritis: Results from the National Health and Wellness Survey

Lin,

Krupsky,

Way

et al. 2024

Rheumatol Ther

View full text Add to dashboard Cite

Introduction Psoriatic arthritis (PsA) is a chronic, autoimmune form of arthritis that is associated with a substantial humanistic and economic burden. Potential differences in patient-reported outcomes (PROs) and economic outcomes among groups of varying PsA severity and different races/ethnicities have not been well studied. Methods This cross-sectional study assessed sociodemographic data, PROs, and economic outcomes for participants with PsA from the National Health and Wellness Survey (2018–2020). Multivariable analyses were used to assess the association of self-reported PsA severity and race/ethnicity with health-related quality of life (HRQoL), work productivity and activity impairment (WPAI), healthcare resource utilization (HCRU), and medical costs. Results This study included 1544 participants with PsA (1073 non-Hispanic white, 114 non-Hispanic Black, 223 Hispanic, and 134 Other). Self-reported moderate/severe PsA was associated with significantly worse HRQoL and WPAI, greater HCRU, and higher costs than self-reported mild PsA. Black participants reported more absenteeism (31.11% vs. 16.69%; P = 0.007) and activity impairment (54.27% vs. 47.96%; P = 0.047) than white participants, and fewer healthcare provider (5.93 vs. 7.42; P = 0.039) and rheumatologist visits (0.29 vs. 0.53; P = 0.028) over the past 6 months. No differences in outcomes were observed between Hispanic and white participants. Race/ethnicity moderated the association of perceived PsA severity and PROs and HCRU, such that white participants with self-reported moderate/severe PsA had a higher likelihood of depression ( P < 0.001), lower HRQoL ( P < 0.001), and more emergency room visits ( P = 0.001) than those with self-reported mild PsA. Race/ethnicity did not moderate the relationship of PROs, HCRU, and economic outcomes among Black or Hispanic participants. Conclusion Participants with self-reported moderate/severe PsA reported a greater burden than those with self-reported mild PsA. Black participants had a greater humanistic burden than white participants but reported lower HCRU. Moderation results were driven by white participants, suggesting important differences in PROs, HCRU, and perception of PsA severity across race/ethnicity groups. Small sample sizes in Hispanic and non-Hispanic racial/ethnic groups limited ability to discern differences related to disease severity in these groups. Further research is needed to better understand the differential burden of PsA among individuals with varying perceptions of PsA severity across different racial/ethnic groups. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-024-00717-7.

show abstract

Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry

Cited by 2 publications

References 27 publications

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Patient-Reported and Economic Racial and Ethnic Disparities in Patients with Psoriatic Arthritis: Results from the National Health and Wellness Survey

Contact Info

Product

Resources

About